Inogen (INGN) Stock Price, News & Analysis

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View INGN analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12-month price objectives for Inogen's stock. Their INGN share price targets range from $7.00 to $26.00. On average, they predict the company's stock price to reach $13.67 in the next year. This suggests a possible upside of 92.8% from the stock's current price.
View analysts price targets for INGN or view top-rated stocks among Wall Street analysts.

Inogen's stock was trading at $5.49 at the start of the year. Since then, INGN shares have increased by 29.1% and is now trading at $7.09.
View the best growth stocks for 2024 here.

Inogen saw a drop in short interest in March. As of March 31st, there was short interest totaling 1,690,000 shares, a drop of 9.6% from the March 15th total of 1,870,000 shares. Based on an average trading volume of 616,700 shares, the short-interest ratio is presently 2.7 days.
View Inogen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our INGN earnings forecast.

Inogen will be holding an earnings conference call on Tuesday, May 7th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13745058".

Inogen, Inc. (NASDAQ:INGN) announced its quarterly earnings data on Tuesday, February, 27th. The medical technology company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by $0.49. The medical technology company earned $75.90 million during the quarter, compared to analysts' expectations of $78.09 million. Inogen had a negative trailing twelve-month return on equity of 38.98% and a negative net margin of 32.46%.

Invesco Nasdaq Future Gen 200 ETF holds 6,173 shares of INGN stock, representing 0.60% of its portfolio.

Inogen updated its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $73.0 million-$74.0 million, compared to the consensus revenue estimate of $80.6 million.

70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

Inogen's stock is owned by a number of institutional and retail investors. Top institutional investors include Kingswood Wealth Advisors LLC (0.07%). Insiders that own company stock include Alison Bauerlein, Brenton Taylor, Holdings A/S Novo, Ray Benjamin M Anderson and Raymond Huggenberger.
View institutional ownership trends.

Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.